secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2026-01-20T23:59:59+00:00
Accession:  0001104659-26-004795
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus reports positive Phase 1 soquelitinib data in atopic dermatitis; Phase 2 planned Q1 2026
--------------------------------------------------------------------------------

- Cohort 4: 75% of soquelitinib patients achieved EASI 75 vs 20% placebo; 25% achieved EASI 90 vs 0% placebo.
- Mean EASI reduction at day 56: 72% for soquelitinib vs 40% for placebo; separation statistically significant (p=0.035).
- No new safety signals; AE rates 41.7% soquelitinib vs 50% placebo, all Grade 1-2, no dose modifications.
- Activity seen in patients with prior systemic therapy including dupilumab/JAK inhibitors.
- Plans to initiate Phase 2 trial in moderate-to-severe atopic dermatitis in Q1 2026 (approx. 200 patients, 4 arms).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000110465926004795/0001104659-26-004795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000110465926004795/tm263501d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-004795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer